High Expression of c-Met, PKCλ and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer

Hitomi Motomura, Yuka Nozaki, Chotaro Onaga, Ayaka Ozaki, Shoma Tamori, Taka Aki Shiina, Shotaro Kanai, Chihiro Ohira, Yasushi Hara, Yohsuke Harada, Ryoko Takasawa, Takehisa Hanawa, Sei Ichi Tanuma, Yasunari Mano, Tsugumichi Sato, Keiko Sato, Kazunori Akimoto

Research output: Contribution to journalArticle

Abstract

Background/Aim: Co-expression of c-Met and ALDH1A3 indicates a poor prognosis in stage III-IV breast cancers and contributes to cell proliferation and tumor formation by ALDH1-positive breast CSCs. PKCλ is overexpressed and contributes to a poor prognosis in several cancers. Materials and Methods: A breast cancer genomics data set (METABRIC, n=2509) was downloaded and analyzed, as was the effect c-Met and PKCλ inhibitors on ALDH1high cell viability and tumor-sphere formation. Results: c-Met expression correlates with expression of PKCλ in breast cancer. Stage III-IV breast cancer patients with c-Methigh PKCλhigh ALDH1A3high have a poorer prognosis than patients with c-Metlow PKCλlow ALDH1A3low. Foretinib and auranofin suppressed cell viability and tumor-sphere formation by ALDH1high cells. These results suggest that c-Met and PKCλ are cooperatively involved in cancer progression and contribute to poor prognoses in breast cancer. Conclusion: c-Met and PKCλ are potentially useful prognostic markers and therapeutic targets in late-stage breast cancer.

Original languageEnglish
Pages (from-to)35-52
Number of pages18
JournalAnticancer research
Volume40
Issue number1
DOIs
Publication statusPublished - 1 Jan 2020

Fingerprint

Breast Neoplasms
Neoplasms
Cell Survival
Auranofin
Genomics
Breast
Cell Proliferation
Therapeutics

Keywords

  • ALDH1A3
  • Breast cancer
  • C-Met
  • Cancer stem cell
  • PKCλ

Cite this

Motomura, Hitomi ; Nozaki, Yuka ; Onaga, Chotaro ; Ozaki, Ayaka ; Tamori, Shoma ; Shiina, Taka Aki ; Kanai, Shotaro ; Ohira, Chihiro ; Hara, Yasushi ; Harada, Yohsuke ; Takasawa, Ryoko ; Hanawa, Takehisa ; Tanuma, Sei Ichi ; Mano, Yasunari ; Sato, Tsugumichi ; Sato, Keiko ; Akimoto, Kazunori. / High Expression of c-Met, PKCλ and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer. In: Anticancer research. 2020 ; Vol. 40, No. 1. pp. 35-52.
@article{f51105fe664c43ef99e225877f3638da,
title = "High Expression of c-Met, PKCλ and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer",
abstract = "Background/Aim: Co-expression of c-Met and ALDH1A3 indicates a poor prognosis in stage III-IV breast cancers and contributes to cell proliferation and tumor formation by ALDH1-positive breast CSCs. PKCλ is overexpressed and contributes to a poor prognosis in several cancers. Materials and Methods: A breast cancer genomics data set (METABRIC, n=2509) was downloaded and analyzed, as was the effect c-Met and PKCλ inhibitors on ALDH1high cell viability and tumor-sphere formation. Results: c-Met expression correlates with expression of PKCλ in breast cancer. Stage III-IV breast cancer patients with c-Methigh PKCλhigh ALDH1A3high have a poorer prognosis than patients with c-Metlow PKCλlow ALDH1A3low. Foretinib and auranofin suppressed cell viability and tumor-sphere formation by ALDH1high cells. These results suggest that c-Met and PKCλ are cooperatively involved in cancer progression and contribute to poor prognoses in breast cancer. Conclusion: c-Met and PKCλ are potentially useful prognostic markers and therapeutic targets in late-stage breast cancer.",
keywords = "ALDH1A3, Breast cancer, C-Met, Cancer stem cell, PKCλ",
author = "Hitomi Motomura and Yuka Nozaki and Chotaro Onaga and Ayaka Ozaki and Shoma Tamori and Shiina, {Taka Aki} and Shotaro Kanai and Chihiro Ohira and Yasushi Hara and Yohsuke Harada and Ryoko Takasawa and Takehisa Hanawa and Tanuma, {Sei Ichi} and Yasunari Mano and Tsugumichi Sato and Keiko Sato and Kazunori Akimoto",
year = "2020",
month = "1",
day = "1",
doi = "10.21873/anticanres.13924",
language = "English",
volume = "40",
pages = "35--52",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

Motomura, H, Nozaki, Y, Onaga, C, Ozaki, A, Tamori, S, Shiina, TA, Kanai, S, Ohira, C, Hara, Y, Harada, Y, Takasawa, R, Hanawa, T, Tanuma, SI, Mano, Y, Sato, T, Sato, K & Akimoto, K 2020, 'High Expression of c-Met, PKCλ and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer', Anticancer research, vol. 40, no. 1, pp. 35-52. https://doi.org/10.21873/anticanres.13924

High Expression of c-Met, PKCλ and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer. / Motomura, Hitomi; Nozaki, Yuka; Onaga, Chotaro; Ozaki, Ayaka; Tamori, Shoma; Shiina, Taka Aki; Kanai, Shotaro; Ohira, Chihiro; Hara, Yasushi; Harada, Yohsuke; Takasawa, Ryoko; Hanawa, Takehisa; Tanuma, Sei Ichi; Mano, Yasunari; Sato, Tsugumichi; Sato, Keiko; Akimoto, Kazunori.

In: Anticancer research, Vol. 40, No. 1, 01.01.2020, p. 35-52.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High Expression of c-Met, PKCλ and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer

AU - Motomura, Hitomi

AU - Nozaki, Yuka

AU - Onaga, Chotaro

AU - Ozaki, Ayaka

AU - Tamori, Shoma

AU - Shiina, Taka Aki

AU - Kanai, Shotaro

AU - Ohira, Chihiro

AU - Hara, Yasushi

AU - Harada, Yohsuke

AU - Takasawa, Ryoko

AU - Hanawa, Takehisa

AU - Tanuma, Sei Ichi

AU - Mano, Yasunari

AU - Sato, Tsugumichi

AU - Sato, Keiko

AU - Akimoto, Kazunori

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Background/Aim: Co-expression of c-Met and ALDH1A3 indicates a poor prognosis in stage III-IV breast cancers and contributes to cell proliferation and tumor formation by ALDH1-positive breast CSCs. PKCλ is overexpressed and contributes to a poor prognosis in several cancers. Materials and Methods: A breast cancer genomics data set (METABRIC, n=2509) was downloaded and analyzed, as was the effect c-Met and PKCλ inhibitors on ALDH1high cell viability and tumor-sphere formation. Results: c-Met expression correlates with expression of PKCλ in breast cancer. Stage III-IV breast cancer patients with c-Methigh PKCλhigh ALDH1A3high have a poorer prognosis than patients with c-Metlow PKCλlow ALDH1A3low. Foretinib and auranofin suppressed cell viability and tumor-sphere formation by ALDH1high cells. These results suggest that c-Met and PKCλ are cooperatively involved in cancer progression and contribute to poor prognoses in breast cancer. Conclusion: c-Met and PKCλ are potentially useful prognostic markers and therapeutic targets in late-stage breast cancer.

AB - Background/Aim: Co-expression of c-Met and ALDH1A3 indicates a poor prognosis in stage III-IV breast cancers and contributes to cell proliferation and tumor formation by ALDH1-positive breast CSCs. PKCλ is overexpressed and contributes to a poor prognosis in several cancers. Materials and Methods: A breast cancer genomics data set (METABRIC, n=2509) was downloaded and analyzed, as was the effect c-Met and PKCλ inhibitors on ALDH1high cell viability and tumor-sphere formation. Results: c-Met expression correlates with expression of PKCλ in breast cancer. Stage III-IV breast cancer patients with c-Methigh PKCλhigh ALDH1A3high have a poorer prognosis than patients with c-Metlow PKCλlow ALDH1A3low. Foretinib and auranofin suppressed cell viability and tumor-sphere formation by ALDH1high cells. These results suggest that c-Met and PKCλ are cooperatively involved in cancer progression and contribute to poor prognoses in breast cancer. Conclusion: c-Met and PKCλ are potentially useful prognostic markers and therapeutic targets in late-stage breast cancer.

KW - ALDH1A3

KW - Breast cancer

KW - C-Met

KW - Cancer stem cell

KW - PKCλ

UR - http://www.scopus.com/inward/record.url?scp=85077430103&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13924

DO - 10.21873/anticanres.13924

M3 - Article

C2 - 31892551

AN - SCOPUS:85077430103

VL - 40

SP - 35

EP - 52

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -